13.7 C
New York
Saturday, November 26, 2022

Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual – Yahoo Finance

-New preclinical data on lead in vivo programming program, MT-302, demonstrates strong expression and favorable safety in myeloid cells following a single administration in non-human primates; IND filing for MT-302 expected in 2023-
CAMBRIDGE, Mass., Nov. 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today presented multiple posters on its therapeutics platforms, ATAK™ CAR receptors and in vivo mRNA programming, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA, November 8-12, 2022.
“The data presented at SITC further highlight the power of Myeloid’s platform to enable broad immune responses and attack cancer cells, supporting the accelerated development of our deep clinical and preclinical  pipeline,” said Daniel Getts, Ph.D., CEO of Myeloid.  “In particular, we are really excited about the progress we’ve made with in vivo programming with MT-302, our TROP2-FcA-LNP, that has shown confirmed tumor killing activity and strong expression in myeloid cells in non-human primates.  We are planning to advance this program into the clinic and expect to file an IND in 2023.”
Myeloid has combined the power of mRNA with proprietary  ATAK™ CAR receptors, to program myeloid cells to target and kill cancer through direct mechanisms and the elicitation of a broad anti-tumor responses, including the activation of T cells.  Myeloid cells are a primary orchestrator of immune response and accumulate naturally within solid tumors, in some cases representing up to seventy-five percent of the tumor mass.   Myeloid’s adaptations of mRNA for the myeloid compartment have enabled the evolution to deliver these receptors directly to the patient without any ex-vivo cell engineering.
Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity.  Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in selective uptake and expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models.  These data demonstrate the potential for Myeloid’s technology to program cells directly in vivo.
Myeloid’s lead program from this platform, MT-302, is a TROP2-FcA-LNP currently in IND-enabling studies for the treatment of multiple indications including colon, lung and breast cancer.  MT-302 has demonstrated strong expression and favorable safety in myeloid cells in two species, rodents and non-human primates.  In addition, treatment with MT-302 demonstrates monotherapy activity in a TROP2/TNBC model, confirming the potency of programmed myeloid cells in the absence of T cells.  Myeloid believes that MT-302 has significant advantages over TROP2-ADC approaches through its ability to engage the full immune response.
Myeloid’s novel class of CARs, known as ATAK™ Receptors, combine tumor recognition with multiple proprietary innate-immune signaling domains.  Myeloid scientists have screened multiple unexplored combinations of innate-immune signals and uncovered optimal multi-signal pathways.  The combination of cancer recognition binders with these novel intracellular signaling domains allows myeloid cells to be reprogrammed with previously unexplored combinations of immune signals, leading to tumor killing and broad systemic anti-tumor responses that support their clinical development in cell therapies.
SITC poster details:
Title: “ATAK receptors, a new class of chimeric antigen receptors that harness innate immunity in myeloid cells to target cancer” 
Poster Number: 393
Session: Cellular Therapies
Date and Time:  November 10, 2022 9:00 am9:00 pm
Title: “In vivo programming of myeloid cells by mRNA-mediated delivery of novel Fc alpha fusion receptor activates anti-tumor immunity
Poster Number: 1237
Session: Immuno-Engineering
Date and Time:  November 10, 2022 9:00 am9:00 pm
The SITC abstracts have been published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC), the society’s global, open access, peer-reviewed journal.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company harnessing the power of myeloid cell biology to engineer new therapeutic alternatives for patients with cancer and autoimmune diseases. Integrating the fields of RNA biology, immunology, and medicine, the Company’s proprietary platform provides clinical solutions that match therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. Myeloid is advancing a broad portfolio of clinical and preclinical candidates designed to enable full immune system responses. Myeloid has entered into strategic partnerships with Prime Medicine and Acuitas and is supported by well-known biotechnology investors. Myeloid is headquartered in Boston, MA.
For more information, please visit https://www.myeloidtx.com/.
Investor and Media Contact
Amy Conrad
Juniper Point
View original content to download multimedia:https://www.prnewswire.com/news-releases/myeloid-therapeutics-presents-update-on-myeloid-cell-programming-technologies-including-non-human-primate-proof-of-concept-data-delivering-in-vivo-mrna-trop-2-targeting-car-mt-302-at-society-for-immunotherapy-of-cancer-sitc-3-301674512.html
SOURCE Myeloid Therapeutics
Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.
Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.
Swiss pharmaceutical company Roche said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year.
The BQ.1 and BQ.1.1 omicron sublineages jointly accounted for more coronavirus cases in the U.S. in the week through Nov. 12 than the BA.5 omicron variant, according to data from the Centers for Disease Control and Prevention.
"While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer's dataset to the field," Roche said.
Ontario is facing a "triple threat" of viruses, COVID-19, influenza and respiratory syncytial virus (RSV), contributing to "extraordinary pressure" on the pediatric healthcare system.
Geoffrey Seymour discovered blood in his stool just before his 41st birthday, which turned out to be stage four cancer
(Reuters) -Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as leaders in a high-stakes race to launch a treatment for the memory-robbing disease. Roche said in a statement on Monday that twin studies known as Graduate 1 and 2 had not reached their main goal of showing that the drug gantenerumab could preserve abilities such as remembering, solving problems, orientation and personal care in patients suffering from early stages of Alzheimer's disease. Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo.
The disappointing results come weeks after a similar treatment developed by two competitors delivered promising data, infusing fresh hope into a field that has been marked by a string of failures.
Even before the COVID-19 pandemic changed the way we monitored our health, the public was no stranger to dealing with seasonal viruses like the flu. According to a study from the Centers for Disease Control and Prevention (CDC), an average of eight percent of the U.S. population becomes sick with it each season. But the well-known virus can still behave differently from year to year, making some winters particularly difficult with higher case counts, increased hospitalizations, and higher-than-a
Public health experts continue to warn about a trifecta of illnesses — RSV, flu and COVID — that are swirling in many parts of the country.
The company said it would keep working on novel diagnostics and treatments for Alzheimer's and said it would present at the Clinical Trials on Alzheimer's Disease Conference.
It's not always easy to discern between normal signs of aging and potential warning signals of cognitive decline. But since there is no cure for diseases like Alzheimer's, Lewy body dementia, and vascular dementia, catching them early is key. "An early diagnosis… can improve the quality of care and quality of life and may reduce the financial and emotional impact of the disease," the Alzheimer's Association explains.Dementia is also on the rise. "Rates of Alzheimer's disease deaths increased mor
Flu season's positivity rate in Los Angeles County is at 25%, up from 13% a week ago, as RSV and COVID are still in circulation.
Anyone experiencing symptoms should see a GP immediately
Five people were taken into custody and two guns were recovered following the incident. No officers were injured, officials said.
Is It RSV, COVID-19 or the flu?
Masks work against not only COVID-19 but also the flu, RSV, and other respiratory viruses. We should still be using them
The fire chiefs activated mass casualty procedures, which allowed two crews to care for all non-urgent EMS patients and got others back into service.
The U.S. Centers for Disease Control and Prevention says to take caution when consuming cold cuts and deli-derived cheeses.


Related Articles


Please enter your comment!
Please enter your name here

Latest Articles